1 week Ago By ABMN Staff
Arrowstreet Capital Limited Partnership purchased a new position in Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH – Free Report ) (TSE:AUP) in the fourth quarter, Holdings Channel.com reports.
The firm purchased 1,075,911 shares of the biotechnology company’s stock, valued at approximately $9,662,000. Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co.
boosted its holdings in Aurinia Pharmaceuticals by 84.4% in the fourth quarter. JPMorgan Chase & Co.
now owns 927,298 shares of the biotechnology company’s stock worth $8,327,000 after purchasing an additional 424,482 shares during the last quarter. Barclays PLC boosted its stake in shares of Aurinia Pharmaceuticals by 187.6% in the 3rd quarter.
Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after buying an additional 143,072 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Aurinia Pharmaceuticals by 6.
9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock worth $15,535,000 after buying an additional 112,113 shares during the last quarter.
Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Aurinia Pharmaceuticals by 22.5% in the fourth quarter.
Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock worth $4,997,000 after acquiring an additional 102,195 shares during the period. Finally, American Century Companies Inc.
increased its position in Aurinia Pharmaceuticals by 124.2% during the fourth quarter. American Century Companies Inc.
now owns 171,590 shares of the biotechnology company’s stock valued at $1,541,000 after acquiring an additional 95,066 shares during the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Trading Down 3.0 % Shares of Aurinia Pharmaceuticals stock opened at $7.81 on Monday.
The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.
11. The stock has a market capitalization of $1.07 billion, a PE ratio of -52.
06 and a beta of 1.26. Aurinia Pharmaceuticals Inc.
has a 1-year low of $4.71 and a 1-year high of $10.67.
The company’s fifty day simple moving average is $8.10 and its 200-day simple moving average is $8.09.
Insider Activity at Aurinia Pharmaceuticals Wall Street Analyst Weigh In Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th. Get Our Latest Report on AUPH Aurinia Pharmaceuticals Company Profile ( Free Report ) Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd. Read More Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH – Free Report ) (TSE:AUP). Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
